KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Assets: 2020-2025

Historic Assets for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Ginkgo Bioworks Holdings' Assets fell 19.70% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 19.70%. This contributed to the annual value of $1.4 billion for FY2024, which is 17.29% down from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' Assets stood at $1.2 billion, which was down 3.40% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' Assets registered a high of $2.5 billion during Q4 2022, and its lowest value of $1.2 billion during Q3 2025.
  • Its 3-year average for Assets is $1.7 billion, with a median of $1.6 billion in 2024.
  • Its Assets has fluctuated over the past 5 years, first surged by 206.74% in 2021, then tumbled by 34.56% in 2024.
  • Quarterly analysis of 5 years shows Ginkgo Bioworks Holdings' Assets stood at $2.1 billion in 2021, then climbed by 22.61% to $2.5 billion in 2022, then crashed by 34.42% to $1.7 billion in 2023, then dropped by 17.29% to $1.4 billion in 2024, then dropped by 19.70% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.